Neovasc Inc (NVCN.CA) Stock Price & Overview

TSX:NVCN • CA64065J4037

40.15 CAD
+0.23 (+0.58%)
Last: Apr 10, 2023, 07:00 PM

The current stock price of NVCN.CA is 40.15 CAD. Today NVCN.CA is up by 0.58%. In the past month the price decreased by -1.21%. In the past year, price increased by 203.02%.

NVCN.CA Key Statistics

52-Week Range6 - 41.2
Current NVCN.CA stock price positioned within its 52-week range.
1-Month Range39.28 - 41.2
Current NVCN.CA stock price positioned within its 1-month range.
Market Cap
110.566M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-142.14
Dividend Yield
N/A

NVCN.CA Stock Performance

Today
+0.58%
1 Week
+1.62%
1 Month
-1.21%
3 Months
+39.90%
Longer-term
6 Months +351.63%
1 Year +203.02%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

NVCN.CA Stock Chart

Neovasc Inc / NVCN Daily stock chart

NVCN.CA Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to NVCN.CA. When comparing the yearly performance of all stocks, NVCN.CA is one of the better performing stocks in the market, outperforming 98.96% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
NVCN.CA Full Technical Analysis Report

NVCN.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NVCN.CA. NVCN.CA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NVCN.CA Full Fundamental Analysis Report

NVCN.CA Earnings

Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ4 / 2022
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
NVCN.CA Earnings History

NVCN.CA Forecast & Estimates


Analysts
Analysts85.71
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
NVCN.CA Forecast & Estimates

NVCN.CA Groups

Sector & Classification

Index Membership

NVCN.CA Financial Highlights

Over the last trailing twelve months NVCN.CA reported a non-GAAP Earnings per Share(EPS) of -142.14. The EPS decreased by -1143.35% compared to the year before.


Income Statements
Revenue(TTM)3.81M
Net Income(TTM)-41.20M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.81
Chartmill High Growth Momentum
EPS Q2Q%-121.5%
Sales Q2Q%91.39%
EPS 1Y (TTM)-1143.35%
Revenue 1Y (TTM)49.47%
NVCN.CA financials

NVCN.CA Ownership

Ownership
Inst Owners0.03%
Shares2.75M
Float2.65M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
NVCN.CA Ownership

NVCN.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
PRN PROFOUND MEDICAL CORP N/A264.917M
TLT THERALASE TECHNOLOGIES INC N/A69.406M
PINK PERIMETER MEDICAL IMAGING AI N/A65.56M
MIR MEDMIRA INC N/A45.499M
CNVI CONAVI MEDICAL CORP N/A41.368M
VPT VENTRIPOINT DIAGNOSTICS LTD N/A20.611M
ASG AURORA SPINE CORP N/A20.077M
NSCI NANALYSIS SCIENTIFIC CORP N/A20.075M
MDX MEDX HEALTH CORP N/A18.036M
THRM THERMA BRIGHT INC N/A3.125M
VVTM VVT MED INC N/A

About NVCN.CA

Company Profile

NVCN logo image Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.

Company Info

IPO: 2001-05-23

Neovasc Inc

Richmond, 5138-13562 Maycrest Way

Richmond British Columbia BRITISH COLUMBIA V6V 2J7 CA

CEO: Fredericus A. Colen

Employees: 71

NVCN Company Website

Phone: 16042704344.0

Neovasc Inc / NVCN.CA FAQ

What does NVCN do?

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.


Can you provide the latest stock price for Neovasc Inc?

The current stock price of NVCN.CA is 40.15 CAD. The price increased by 0.58% in the last trading session.


Does Neovasc Inc pay dividends?

NVCN.CA does not pay a dividend.


What is the ChartMill technical and fundamental rating of NVCN stock?

NVCN.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of Neovasc Inc (NVCN.CA)?

Neovasc Inc (NVCN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-142.14).